Supplemental Table 1. Odds ratios and 95% confidence intervals comparing ACR20[a], ACR50[b], and ACR70[c] responses at Week 24 between guselkumab and placebo within patient subgroups defined by baseline demographics, disease characteristics, and DMARD use at baseline among pooled DISCOVER-1 and DISCOVER-2 patients. Prior to Week 24, patients meeting treatment failure criteria were considered non-responders. Missing data through Weeks 24 and 52 were imputed as non-response.

	ACR20 Response[a]		ACR50 Response[b]		ACR70 Response[c]	
	Odds Ratio (95% CI)					
	GUS 100 mg Q4W	GUS 100 mg Q8W	GUS 100 mg Q4W	GUS 100 mg Q8W	GUS 100 mg Q4W	GUS 100 mg Q8W
All patients	4.0 (2.9, 5.4)	3.6 (2.7, 4.9)	3.7 (2.5, 5.3)	3.2 (2.2, 4.6)	3.8 (2.2, 6.7)	4.1 (2.3, 7.1)
Sex						
Male	4.2 (2.8, 6.5)	3.5 (2.3, 5.4)	3.9 (2.4, 6.4)	3.2 (1.9, 5.4)	3.4 (1.7, 6.9)	3.6 (1.8, 7.3)
Female	3.5 (2.3, 5.5)	3.7 (2.4, 5.7)	3.2 (1.8, 5.6)	3.0 (1.7, 5.4)	4.3 (1.7, 11.0)	4.6 (1.8, 11.7)
BMI (kg/m²)						
<25	4.2 (2.3, 7.7)	2.4 (1.4, 4.3)	4.3 (2.1, 9.1)	3.3 (1.6, 6.8)	6.6 (2.2, 20.0)	4.5 (1.5, 13.9)
25 to <30	4.4 (2.6, 7.5)	4.1 (2.4, 6.9)	2.9 (1.6, 5.4)	2.8 (1.5, 5.1)	2.5 (1.1, 5.8)	3.4 (1.5, 7.7)
≥30	3.7 (2.3, 5.9)	4.3 (2.6, 7.0)	4.2 (2.2, 8.1)	3.6 (1.9, 7.0)	4.6 (1.5, 13.8)	5.1 (1.7, 15.4)
Swollen joint count						
<10	5.1 (3.3, 7.8)	3.3 (2.2, 5.0)	5.5 (3.2, 9.2)	4.1 (2.4, 6.9)	6.4 (2.9, 14.0)	5.1 (2.3, 11.3)
10-15	3.1 (1.7, 5.5)	4.1 (2.3, 7.4)	2.5 (1.3, 5.0)	2.1 (1.0, 4.2)	2.2 (0.7, 6.8)	2.3 (0.7, 6.8)
>15	3.2 (1.6, 6.2)	4.1 (2.1, 8.2)	2.1 (0.8, 5.2)	2.9 (1.2, 7.2)	1.4 (0.4, 5.3)	4.2 (1.3, 13.4)
Tender joint count						
<10	7.9 (3.5, 17.7)	4.5 (2.1, 9.8)	9.9 (3.5, 27.6)	6.3 (2.2, 17.9)	10.3 (2.3, 46.2)	9.2 (2.0, 41.6)
10-15	4.7 (2.6, 8.4)	3.5 (2.0, 6.0)	4.7 (2.4, 9.2)	3.3 (1.7, 6.4)	5.2 (1.9, 14.5)	3.8 (1.4, 10.7)
>15	3.0 (2.0, 4.5)	3.5 (2.3, 5.3)	2.2 (1.3, 3.7)	2.5 (1.5, 4.2)	1.9 (0.9, 4.3)	3.0 (1.4, 6.5)
PsA duration (years)						
<1	3.6 (1.7, 7.9)	6.8 (3.0, 14.9)	6.3 (2.2, 18.0)	7.4 (2.6, 20.7)	5.3 (1.1, 25.4)	9.0 (2.0, 40.8)
≥1 to <3	6.2 (3.2, 11.8)	4.0 (2.1, 7.4)	5.3 (2.5, 11.4)	3.4 (1.5, 7.3)	7.0 (2.3, 21.3)	3.2 (1.0, 10.5)
≥3	3.5 (2.4, 5.2)	2.9 (2.0, 4.3)	2.8 (1.7, 4.5)	2.4 (1.5, 3.9)	2.7 (1.3, 5.6)	3.3 (1.6, 6.8)
CRP (mg/dL)						
<1	4.0 (2.6, 6.1)	3.7 (2.4, 5.6)	4.5 (2.6, 7.7)	3.9 (2.2, 6.7)	6.6 (2.7, 16.1)	5.9 (2.4, 14.6)
1 to <2	8.3 (3.9, 17.6)	7.7 (3.6, 16.7)	5.9 (2.4, 14.5)	4.6 (1.8, 11.6)	4.9 (1.0, 23.3)	5.8 (1.2, 27.5)
≥2	2.5 (1.4, 4.4)	2.4 (1.4, 4.0)	1.9 (1.0, 3.8)	2.0 (1.0, 3.7)	1.7 (0.7, 4.3)	2.4 (1.0, 5.6)
csDMARD/MTX use						
None	6.6 (3.7, 11.6)	5.6 (3.2, 9.8)	4.9 (2.4, 9.8)	5.0 (2.5, 10.1)	10.0 (2.9, 34.1)	9.9 (2.9, 33.7)
Any csDMARD	3.2 (2.2, 4.6)	3.0 (2.1, 4.3)	3.2 (2.1, 5.1)	2.6 (1.6, 4.0)	2.6 (1.3, 5.0)	2.8 (1.5, 5.4)
MTX	3.6 (2.4, 5.3)	2.8 (1.9, 4.2)	3.4 (2.1, 5.4)	2.3 (1.4, 3.8)	3.1 (1.5, 6.4)	3.3 (1.6, 6.8)

[a,b,c]≥20%, ≥50%, and ≥70%, respectively, improvement from baseline in both tender joint count (68 joints) and swollen joint count (66 joints), and ≥20%, ≥50%, and ≥70%, respectively, improvement from baseline in at least 3 of the 5 assessments: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, HAQ-DI, and CRP.

ACR20/50/70=American College of Rheumatology 20/50/70% improvement, BMI=Body mass index, CI=confidence interval, CRP=C-reactive protein, csDMARD=Conventional synthetic disease-modifying antirheumatic drug, GUS=Guselkumab, MTX=Methotrexate, PsA=Psoriatic arthritis, Q4W/Q8W=every four weeks/every eight weeks